Safety Reading Notes

Read safety context beside the research guide.

The CB2 receptor pharmacology source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 17828291

PubMed For Dummies Article

CB2 receptor pharmacology Evidence Review: the long-form source walk-through

Quick read
  • CB2 receptor pharmacology currently has 32 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 17828291
  • The evidence classes most visible in the row language are insufficient (17), and mechanistic or pharmacological (15). PMID 39288632
  • The study-design language most visible in the row language is Narrative or expert review (17), Animal study (5), and Cellular or in vitro study (1). PMID 18537620
  • The repeated topics are CB2 (32), which tells the reader where to start opening PubMed and DOI links. PMID 26698193

Start with the research question

CB2 receptor pharmacology is built from 32 source-backed evidence row(s) and 32 research source(s). The current evidence classes read as insufficient (17), and mechanistic or pharmacological (15), and the study-design language most often reads as Narrative or expert review (17), Animal study (5), and Cellular or in vitro study (1). PMID 17828291

The row-level question is not simply whether CB2 receptor pharmacology is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are CB2 (32). PMID 31368508

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 31368508

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 12505686

Mechanistic evidence 15 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 10469884

Limits and uncertainty 17 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 33811300

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 40271066

Where this page has the most source density

The largest bucket surfaced for this page is CB2: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB2: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 17828291

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 31368508

Bucket chapters: what the literature is circling

CB2: insufficient

17 research sources 17 rows (863-894) Evidence class: insufficient

This bucket summarizes source-backed rows focused on CB2: insufficient. It currently draws from 17 research source(s), so the exact study type matters. PMID 17828291

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 17828291

  • Evidence row 863

    THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or s... PMID 17828291

  • Evidence row 894

    Anandamide modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16596776

CB2: mechanistic or pharmacological

15 research sources 15 rows (867-888) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on CB2: mechanistic or pharmacological. It currently draws from 15 research source(s), so the exact study type matters. PMID 31368508

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 31368508

  • Evidence row 867

    THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 receptor pharmacology, ligand bind... PMID 31368508

  • Evidence row 888

    Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36922494

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (15 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 17828291

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 31368508

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 28826535
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 9336020
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 26124120

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 17828291

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 31368508

Source-reading checklist for CB2 receptor pharmacology

  1. Open the linked PubMed or DOI record. PMID 34684770
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 30639103
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 32004460
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 28220706
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 36889269

Source Notes

CB2 receptor pharmacology source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 863

    THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 17828291

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
  2. Evidence row 864

    Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 39288632

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).
  3. Evidence row 865

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 18537620

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
  4. Evidence row 866

    THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 26698193

    Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
  5. Evidence row 867

    THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 31368508

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene is a cannabinoid CB2 receptor agonist.
  6. Evidence row 868

    Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 12505686

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
  7. Evidence row 869

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 10469884

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid receptor ligands.
  8. Evidence row 870

    THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 33811300

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
  9. Evidence row 871

    THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 40271066

    Evidence class: mechanistic or pharmacological. Source: A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay.
  10. Evidence row 872

    Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 28826535

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Functional Selectivity at Cannabinoid Receptors.
  11. Evidence row 873

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 9336020

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid CB1 and CB2 receptors.
  12. Evidence row 874

    THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 26124120

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.
  13. Evidence row 875

    Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 34684770

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Spicy Story of Cannabimimetic Indoles.
  14. Evidence row 876

    Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 30639103

    Evidence class: mechanistic or pharmacological. Source: Crystal Structure of the Human Cannabinoid Receptor CB2.
  15. Evidence row 877

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 32004460

    Evidence class: mechanistic or pharmacological. Source: Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.
  16. Evidence row 878

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 28220706

    Evidence class: mechanistic or pharmacological. Source: Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.
  17. Evidence row 879

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36889269

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A Cannabinoid Type 2 (CB2) Receptor Agonist Augments NOS-Dependent Responses of Cerebral Arterioles During Type 1 Diabetes.
  18. Evidence row 880

    Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 33749323

    Evidence class: mechanistic or pharmacological. Source: CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.
  19. Evidence row 881

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 11514083

    Evidence class: mechanistic or pharmacological. Source: CB2 cannabinoid receptor-mediated peripheral antinociception.
  20. Evidence row 882

    Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 27215781

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.
  21. Evidence row 883

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16563625

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor mediation of antinociception.
  22. Evidence row 884

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36058263

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The Cannabinoid-2 receptor agonist, 1-phenylisatin, protects against cisplatin-induced nephrotoxicity in mice.
  23. Evidence row 885

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 34774714

    Evidence class: mechanistic or pharmacological. Source: Cannabinoid Receptor Type 2 Agonist Reduces Morphine Tolerance via Mitogen Activated Protein Kinase Phosphatase Induction and Mitogen Activated Protein Kinase Dephosphorylation.
  24. Evidence row 886

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 27608434

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats.
  25. Evidence row 887

    THC modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 20849866

    Evidence class: mechanistic or pharmacological. Source: The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.
  26. Evidence row 888

    Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36922494

    Evidence class: mechanistic or pharmacological. Source: Structural basis of selective cannabinoid CB2 receptor activation.
  27. Evidence row 889

    Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 38886185

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).
  28. Evidence row 890

    Anandamide modulates CB2; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16678907

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
  29. Evidence row 891

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 37349984

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB2 receptor orthologues; in vitro function and perspectives for preclinical to clinical translation.
  30. Evidence row 892

    Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36028971

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential.
  31. Evidence row 893

    THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 29980914

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
  32. Evidence row 894

    Anandamide modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16596776

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Structural requirements for cannabinoid receptor probes.